肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 加拿大共识声明：放射性碘耐药分化型甲状腺癌的管理

2021-08-10 国外肿瘤科相关专家小组（统称） Oral Oncol. 2021 Aug 10;121:105477.

甲状腺癌

放射性碘耐药分化型甲状腺癌 (RAIRTC) 是一种侵袭性甲状腺癌，临床少见且具有异质性。RAIRTC本文主要针对RAIRTC的诊断和管理提供了一些了专家共识，提供了RAIRTC的所学科管理模式指南。

中文标题：

2021 加拿大共识声明：放射性碘耐药分化型甲状腺癌的管理

英文标题：

Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2021-08-10

简要介绍：

放射性碘耐药分化型甲状腺癌 (RAIRTC) 是一种侵袭性甲状腺癌，临床少见且具有异质性。RAIRTC本文主要针对RAIRTC的诊断和管理提供了一些了专家共识，提供了RAIRTC的所学科管理模式指南。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=021 加拿大共识声明：放射性碘耐药分化型甲状腺癌的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8fafb1c002165a32, title=2021 加拿大共识声明：放射性碘耐药分化型甲状腺癌的管理, enTitle=Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer, guiderFrom=Oral Oncol. 2021 Aug 10;121:105477., authorId=0, author=, summary=放射性碘耐药分化型甲状腺癌 (RAIRTC) 是一种侵袭性甲状腺癌，临床少见且具有异质性。RAIRTC本文主要针对RAIRTC的诊断和管理提供了一些了专家共识，提供了RAIRTC的所学科管理模式指南。, cover=https://img.medsci.cn/2021829/1630244010353_2020535.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Tue Aug 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>放射性碘耐药分化型甲状腺癌 (RAIRTC) 是一种侵袭性甲状腺癌，临床少见且具有异质性。RAIRTC本文主要针对RAIRTC的诊断和管理提供了一些了专家共识，提供了RAIRTC的所学科管理模式指南。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=865, tagName=甲状腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=865, guiderKeyword=甲状腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3898, appHits=65, showAppHits=0, pcHits=231, showPcHits=3833, likes=1, shares=6, comments=3, approvalStatus=1, publishedTime=Sun Aug 29 22:36:14 CST 2021, publishedTimeString=2021-08-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Aug 29 21:33:39 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Wed Jan 03 01:55:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=021 加拿大共识声明：放射性碘耐药分化型甲状腺癌的管理.pdf)])
021 加拿大共识声明：放射性碘耐药分化型甲状腺癌的管理.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2139965, encodeId=e5d02139965f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Tue May 30 20:47:19 CST 2023, time=2023-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125502, encodeId=ac8821255021a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:03 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125500, encodeId=da6c212550072, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:48 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省)]
    2023-05-30 1471d48dm72暂无昵称 来自安徽省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2139965, encodeId=e5d02139965f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Tue May 30 20:47:19 CST 2023, time=2023-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125502, encodeId=ac8821255021a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:03 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125500, encodeId=da6c212550072, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:48 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省)]
    2023-04-12 1471d48dm72暂无昵称 来自安徽省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2139965, encodeId=e5d02139965f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Tue May 30 20:47:19 CST 2023, time=2023-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125502, encodeId=ac8821255021a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:03 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2125500, encodeId=da6c212550072, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:22:48 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省)]
    2023-04-12 1471d48dm72暂无昵称 来自安徽省

    学习了

    0

相关指南

儿童甲状腺癌诊疗规范(2021年版)

中华人民共和国国家卫生健康委员会 · 2021-05-13

2021 ATA指南： 未分化甲状腺癌患者的管理

美国甲状腺协会(ATA,American Thyroid Association) · 2021-03-20

甲状腺癌基因检测与临床应用广东专家共识（2020版）

暂未更新 · 2020-03-20

妊娠期和产后分化型甲状腺癌促甲状腺激素抑制治疗中国专家共识（2019版）

中国医师协会外科医师分会 · 2020-03-15

2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理

国外肿瘤科相关专家小组（统称） · 2019-12-13

2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2019-09-24

拓展阅读

2009 ATA 甲状腺结节和分化型甲状腺癌指南修订版

美国甲状腺协会(ATA,American Thyroid Association) · 2009-12-01

分化型甲状腺癌诊治指南

中国抗癌协会头颈肿瘤外科专业委员会 · 2010-10-01

2012 ESMO临床实践指南：甲状腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012中国甲状腺结节和分化型甲状腺癌指南

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2012-08-08

2012ATA 未分化甲状腺癌管理指南

美国甲状腺协会(ATA,American Thyroid Association) · 2012-11-06

2013 ETA颈部超声扫描和超声引导技术在甲状腺癌患者术后管理中的应用指南

欧洲甲状腺协会(ETA,European Thyroid Association) · 2013-09-05